Watson Pharmaceuticals

Watson Pharmaceuticals, Inc. (NYSE: WPI) is a leading integrated global pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, brand and biologic pharmaceutical products. Watson is among the top five pharmaceutical companies in the United States, based on total prescriptions, and has commercial operations in many of the world’s established and emerging international markets. Our largest commercial market is the United States, followed by our key international markets including Western Europe, Canada, Asia/Pacific, South America and South Africa.

Overall Key Business Highlights in 2010
Generated Net Revenues of $3.57 billion
Expanded Generics Portfolio/Pipeline: 7 U.S. product launches; filed 34 ANDAs with 120+ pending; filed 145 applications globally; disclosed 17 new patent challenges including gx Lidoderm® and agreement for date-certain launch of gx CONCERTA®; and entered new high-growth emerging markets of Brazil & Mexico
Expanded Brand Portfolio/Pipeline: 3 U.S. product launches; completed Prochieve® clinical trial; development license for Esmya™ for uterine fibroids; and initiated rFSH biologic project
Enhanced Global Supply Chain: applied Watson Operational Excellence Initiative to global locations; consolidated global manufacturing and R&D footprint; and created Generic Portfolio Management function to speed product launches.

Type:	NORMAL
Address:	21-22 Kalpataru Square Kondivita Lane, Off Andheri Kurla Road. Andheri East. Mumbai - 400 059, India
Website:	http://www.watson.com/
Phone:	+91 (0)22 6688 6700
Fax:	+91 (0)22 6688 6799